Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxazosin mesylate
Drug ID BADD_D00719
Description Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Indications and Usage Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension.[L7282] Off-label uses of doxazosin include the treatment of pediatric hypertension[A180634] and the treatment of ureteric calculi.[A180637]
Marketing Status approved
ATC Code C02CA04
DrugBank ID DB00590
KEGG ID D00608
MeSH ID D017292
PubChem ID 62978
TTD Drug ID D03MIR
NDC Product Code 0832-0356; 53869-2780; 65427-012; 43353-646; 71610-251; 17511-113; 53869-2710; 53869-2720; 0049-2780; 71610-110; 59762-2380; 0832-1359; 43353-740; 50090-6298; 71335-9672; 65862-204; 50090-3143; 51655-130; 62135-051; 53869-2740; 55111-005; 0093-2067; 59762-2340; 71610-120; 0832-1358; 53104-7521; 0093-2070; 43353-739; 53808-1107; 62135-053; 62135-054; 46014-1001; 50090-6401; 0093-2068; 51655-206; 62135-052; 71610-482; 0832-0357; 53747-076; 65427-016; 65427-018; 0093-2069
UNII 86P6PQK0MU
Synonyms Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274
Chemical Information
Molecular Formula C24H29N5O8S
CAS Registry Number 77883-43-3
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation19.06.02.001; 17.02.05.012--
Alopecia23.02.02.001--
Amnesia19.20.01.001; 17.03.02.001--
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Back pain15.03.04.005--
Bradycardia02.03.02.002--Not Available
Breast pain21.05.05.003--
Bronchospasm22.03.01.004; 10.01.03.012--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages